Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

被引：0
|
作者：
S Redaelli
F Boschelli
P Perini
A Pirola
M Viltadi
C Gambacorti-Passerini
机构：
[1] University of Milano-Bicocca,Department of Clinical Medicine and Prevention
[2] S.Gerardo Hospital,undefined
[3] Center for Integrative Biology and Therapeutics,undefined
[4] Pfizer Research,undefined
[5] Pearl River,undefined
[6] NY,undefined
[7] USA. E-mail carlo.gambacorti@unimib.it,undefined
来源：
Leukemia | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1223 / 1227
页数：4
相关论文
共 50 条
  • [21] Bosutinib, a Src/Abl Kinase Inhibitor Induces Apoptosis in CLL B Cells by Targeting Multiple Tyrosine Kinases and Overcomes Stroma Protection
    Ghosh, Asish K.
    Mukhopadhyay, Debabrata
    Kay, Neil E.
    BLOOD, 2009, 114 (22) : 935 - 935
  • [22] Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma
    Taylor, Jennie W.
    Dietrich, Jorg
    Gerstner, Elizabeth R.
    Norden, Andrew D.
    Rinne, Mikael L.
    Cahill, Daniel P.
    Stemmer-Rachamimov, Anat
    Wen, Patrick Y.
    Betensky, Rebecca A.
    Giorgio, Diana H.
    Snodgrass, Kellis
    Randall, Alison E.
    Batchelor, Tracy T.
    Chi, Andrew S.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (03) : 557 - 563
  • [23] Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma
    Jennie W. Taylor
    Jorg Dietrich
    Elizabeth R. Gerstner
    Andrew D. Norden
    Mikael L. Rinne
    Daniel P. Cahill
    Anat Stemmer-Rachamimov
    Patrick Y. Wen
    Rebecca A. Betensky
    Diana H. Giorgio
    Kellis Snodgrass
    Alison E. Randall
    Tracy T. Batchelor
    Andrew S. Chi
    Journal of Neuro-Oncology, 2015, 121 : 557 - 563
  • [24] Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Katagiri, Seiichiro
    Tanaka, Yuko
    Ohyashiki, Kazuma
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [25] Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
    Seiichi Okabe
    Tetsuzo Tauchi
    Seiichiro Katagiri
    Yuko Tanaka
    Kazuma Ohyashiki
    Journal of Hematology & Oncology, 7
  • [26] Antitumor activity of saracatinib, a c-Src/Abl kinase inhibitor, in gastric cancer
    Nam, Hyun-Jin
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Hwang-Phill
    Yoon, Young-Kwang
    Min, Ah-Rum
    Song, Sang-Hyun
    Han, Sae-Won
    Kim, Tae-You
    Bang, Yung-Jue
    CANCER RESEARCH, 2011, 71
  • [27] Overriding imatinib resistance with a novel ABL kinase inhibitor
    Shah, NP
    Tran, C
    Lee, FY
    Chen, P
    Norris, D
    Sawyers, CL
    SCIENCE, 2004, 305 (5682) : 399 - 401
  • [28] The topoisomerase I inhibitor gimatecan exhibits synergistic antitumor activity in combination with imatinib mesylate and everolimus against malignant glioma xenografts
    Vassal, G.
    Hamelin, N.
    Opolon, P.
    Versace, R.
    Geoerger, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification
    Morinaga, Koji
    Yamauchi, Takahiro
    Kimura, Shinya
    Maekawa, Taira
    Ueda, Takanori
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (11) : 2621 - 2627
  • [30] Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro
    Liu, He
    Li, Hongyan
    Feng, Zhiqiang
    Tai, Jun
    Meng, Yang
    Wang, Hongbo
    Xin, Hongqi
    Zhang, Sen
    Zuo, Mingxin
    Zhang, Yan
    Chen, Xiaoguang
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 437 - 446
12345